Scholarlink

Abstract <p>Huntington’s disease (HD) is a neurodegenerative disorder caused by an expanded trinucleotide repeat in the huntingtin gene (<i>HTT</i>) that subsequently leads to aggregation of the mutant huntingtin (mHTT) protein. Thus, lowering mHTT is a key therapeutic approach used by several candidate therapeutics currently under investigation. Visualization of the efficiency of these therapeutics through in vivo mHTT quantification rises in importance. For positron emission tomography (PET) imaging of mHTT aggregates, it is critical to characterize the in vivo kinetic profile of newly identified mHTT binders to assess their translational application. Here, we report the evaluation of [<sup>11</sup>C]CHDI-009R, a PET imaging radioligand with higher affinity and selectivity for mHTT aggregates than previously reported radioligands, in the heterozygous zQ175DN mouse model of HD and wild-type littermates at 9 and 3&#xa0;months of age. [<sup>11</sup>C]CHDI-009R displayed high stability in plasma and brain, which was reflected in brain kinetics as demonstrated by rapid uptake followed by relatively slow elimination. Kinetic modeling and volume of distribution <i>V</i><sub>T&#xa0;(IDIF)</sub> indicated the radioligand's ability to quantify mHTT aggregation at 9&#xa0;months of age with clear genotype differentiation (<i>p</i> &lt; 0.0001). [<sup>11</sup>C]CHDI-009R showed an excellent test–retest reliability in 9-month-old mice (intraclass correlation coefficient: 0.62—0.79). A phenotypic difference in mHTT aggregates was also observed in 3-month-old mice in several brain structures (<i>p</i> &lt; 0.05) and was confirmed with [<sup>3</sup>H]CHDI-009R autoradiography. Overall, this study suggests [<sup>11</sup>C]CHDI-009R is a promising radioligand for the detection of cerebral mHTT aggregates in a mouse model of HD and supports its advance to clinical evaluation.</p> Key messages <p><UnorderedList Mark="Bullet"> <ItemContent> <p>[<sup>11</sup>C]CHDI-009R clearly differentiated between genotypes at low and high mHTT aggregate stages.</p> </ItemContent> <ItemContent> <p>[<sup>11</sup>C]CHDI-009R presented high reproducibility during test–retest imaging.</p> </ItemContent> <ItemContent> <p>Power analyses suggest [<sup>11</sup>C]CHDI-009R as suitable marker for early therapeutic interventions.</p> </ItemContent> </UnorderedList></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preclinical evaluation of [11C]CHDI-009R for quantification of mutant huntingtin aggregates

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Franziska Zajicek,
  • Liesbeth Everix,
  • Annemie Van Eetveldt,
  • Jeroen Verhaeghe,
  • Stef De Lombaerde,
  • Alan Miranda,
  • Jordy Akkermans,
  • Celia Dominguez,
  • Vinod Khetarpal,
  • Jonathan Bard,
  • Longbin Liu,
  • Steven Staelens,
  • Daniele Bertoglio

摘要

Abstract

Huntington’s disease (HD) is a neurodegenerative disorder caused by an expanded trinucleotide repeat in the huntingtin gene (HTT) that subsequently leads to aggregation of the mutant huntingtin (mHTT) protein. Thus, lowering mHTT is a key therapeutic approach used by several candidate therapeutics currently under investigation. Visualization of the efficiency of these therapeutics through in vivo mHTT quantification rises in importance. For positron emission tomography (PET) imaging of mHTT aggregates, it is critical to characterize the in vivo kinetic profile of newly identified mHTT binders to assess their translational application. Here, we report the evaluation of [11C]CHDI-009R, a PET imaging radioligand with higher affinity and selectivity for mHTT aggregates than previously reported radioligands, in the heterozygous zQ175DN mouse model of HD and wild-type littermates at 9 and 3 months of age. [11C]CHDI-009R displayed high stability in plasma and brain, which was reflected in brain kinetics as demonstrated by rapid uptake followed by relatively slow elimination. Kinetic modeling and volume of distribution VT (IDIF) indicated the radioligand's ability to quantify mHTT aggregation at 9 months of age with clear genotype differentiation (p < 0.0001). [11C]CHDI-009R showed an excellent test–retest reliability in 9-month-old mice (intraclass correlation coefficient: 0.62—0.79). A phenotypic difference in mHTT aggregates was also observed in 3-month-old mice in several brain structures (p < 0.05) and was confirmed with [3H]CHDI-009R autoradiography. Overall, this study suggests [11C]CHDI-009R is a promising radioligand for the detection of cerebral mHTT aggregates in a mouse model of HD and supports its advance to clinical evaluation.

Key messages

[11C]CHDI-009R clearly differentiated between genotypes at low and high mHTT aggregate stages.

[11C]CHDI-009R presented high reproducibility during test–retest imaging.

Power analyses suggest [11C]CHDI-009R as suitable marker for early therapeutic interventions.